Olanzapine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00334 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 42 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | benign paroxysmal torticollis of infancy | KG + DL |
| 2 | agoraphobia | KG + DL |
| 3 | dysthymic disorder | KG + DL |
| 4 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 5 | neurotic disorder | KG + DL |
| 6 | neurotic depression | KG + DL |
| 7 | melancholia | KG + DL |
| 8 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 9 | Ohdo syndrome and variants | KG + DL |
| 10 | childhood apraxia of speech | KG + DL |
| 11 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 12 | hydranencephaly (disease) | KG + DL |
| 13 | phobic disorder | KG + DL |
| 14 | syndromic myopia | KG + DL |
| 15 | Malan overgrowth syndrome | KG + DL |
| 16 | myopia X-linked | KG + DL |
| 17 | Keppen-Lubinsky syndrome | KG + DL |
| 18 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 19 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 20 | blepharophimosis - intellectual disability syndrome, Ohdo type | KG + DL |
| 21 | myopia 26, X-linked, female-limited | KG + DL |
| 22 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | KG + DL |
| 23 | atypical glycine encephalopathy | KG + DL |
| 24 | surfactant metabolism dysfunction, pulmonary | KG + DL |
| 25 | congenital isolated adrenocorticotropic hormone deficiency (disease) | KG + DL |
| 26 | autosomal dominant slowed nerve conduction velocity | KG + DL |
| 27 | ligneous conjunctivitis | KG + DL |
| 28 | trichotillomania | KG + DL |
| 29 | vitamin B12-responsive methylmalonic acidemia | KG + DL |
| 30 | gaze palsy, familial horizontal, with progressive scoliosis | KG + DL |
| 31 | autism spectrum disorder | KG + DL |
| 32 | Phelan-McDermid syndrome | KG + DL |
| 33 | chromosome 15q26-qter deletion syndrome | KG + DL |
| 34 | mixed anxiety and depressive disorder | KG + DL |
| 35 | asperger syndrome, susceptibility to | KG + DL |
| 36 | autism susceptibility 1 | KG + DL |
| 37 | chromosome 2P16.3 deletion syndrome | KG + DL |
| 38 | Tourette syndrome | KG + DL |
| 39 | Pitt-Hopkins-like syndrome 2 | KG + DL |
| 40 | amelocerebrohypohidrotic syndrome | KG + DL |
| 41 | familial hypertryptophanemia | KG + DL |
| 42 | obsessive-compulsive disorder | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.